Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Conditions:   Epstein-Barr Virus Infection;   Infectious Mononucleosis;   Herpesvirus Interventions:   Drug: Matrix-M1 Adjuvant;   Drug: EBV gp350-Ferritin Vaccine;   Other: Placebo Comparator Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials